The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database

Title	The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database
Authors	Shun Li,Zhifei Huang,Xiaoyu Zhong,Yan Zhou,Hao Jiang
Magazine	BMC Cancer
Date	04/24/2025
DOI	10.1186/s12885-025-14171-3
Introduction	Lung cancer remains a significant cause of cancer-related deaths globally. This study investigates the impact of combining immune checkpoint inhibitors with chemotherapy, focusing on pembrolizumab's addition to pemetrexed and platinum. Utilizing the FDA's Adverse Event Reporting System, the research evaluates treatment-related toxicity in lung cancer patients. Data from 2017 to 2024 were analysed, revealing that combination therapy presents a higher risk of adverse events such as renal, urinary, and hepatobiliary disorders, and interstitial lung disease. Gender and age are important factors in adverse event occurrence, and monitoring during the first three months of therapy is crucial.
Quote	Shun Li, Zhifei Huang and Xiaoyu Zhong et al. The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database. BMC Cancer. 2025. Vol. 25. DOI: 10.1186/s12885-025-14171-3
Element	Platinum (Pt)
Industry	Pharmaceutical Industry